Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 46 min ago
Peer-reviewedLicence not statedEuropean Urology

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) – A Summary of the 2026 Guidelines Update

  • Paolo Gontero1
  • Paramananthan Mariappan2
  • Benjamin Pradère3
  • Bhavan P. Rai4
  • Fredrik Liedberg5
  • Éva Compérat6
  • Jeremy Yuen‐Chun Teoh7
  • Marco Moschini8
  • Francesco Soria1
  • Bas W.G. van Rhijn9
  • Joyce Baard10
  • Alison Jane Birtle11
12 more authors
  • Maresa Botha12
  • Otakar Čapoun13
  • David D’Andrea14
  • Edoardo Fiorini15
  • A. Masson-Lecomte16
  • Thomas Seisen17
  • Shahrokh François Shariat14
  • Emma J. Smith18
  • Viktor Soukup13
  • Robert Wood12
  • Evanguelos N. Xylinas19
  • Jose Luis Dominguez-Escrig20
20 affiliations
  1. 1Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
  2. 2Edinburgh Bladder Cancer Surgery (EBCS), The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
  3. 3Department of Urology UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France
  4. 4Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  5. 5Institute of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden
  6. 6Department of Pathology, Medical University of Vienna, Vienna, Austria
  7. 7S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
  8. 8Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
  9. 9Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
  10. 10Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
  11. 11Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom
  12. 12EAU Guidelines Office, Arnhem, the Netherlands
  13. 13Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
  14. 14Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
  15. 15Associazione PaLiNUro, Milan, Italy
  16. 16Department of Urology, Université de Paris, APHP, Saint Louis Hospital, Paris, France
  17. 17GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France
  18. 18EAU Guidelines Office, Arnhem, the Netherlands. Electronic address: [email protected]
  19. 19Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, France
  20. 20Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
Open at sourceDOICite

Related

  1. The current landscape of bladder-sparing therapies in BCG-refractory high-risk nonmuscle-invasive bladder cancer.
    Yiqing Gu, Wei He, Xiaowen Yu +4
    Current urologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  2. An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Urinary dual-site proenkephalin (PENK) methylation testing for detection of high-grade or invasive recurrence during surveillance of non-muscle-invasive bladder cancer
    Jiwoong Yu, Wan Song, Minyong Kang +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaCrossref
  4. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer
    Philipp Maisch, Mohammad Hamidi Madani, Alex Koziarz +3
    Cochrane Database of Systematic ReviewsPeer-reviewedPublisher termsFull text19 citedOncologyOpenAlexPMC
  5. FGFR 1–3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis
    Dilek Çağlayan, Emine Göktaş, Makbule Nihan Somuncu +10
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{gontero2026guidelines,
  title = {{EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) – A Summary of the 2026 Guidelines Update}},
  author = {Paolo Gontero and Paramananthan Mariappan and Benjamin Pradère and Bhavan P. Rai and Fredrik Liedberg and Éva Compérat and Jeremy Yuen‐Chun Teoh and Marco Moschini and Francesco Soria and Bas W.G. van Rhijn and Joyce Baard and Alison Jane Birtle and Maresa Botha and Otakar Čapoun and David D’Andrea and Edoardo Fiorini and A. Masson-Lecomte and Thomas Seisen and Shahrokh François Shariat and Emma J. Smith and Viktor Soukup and Robert Wood and Evanguelos N. Xylinas and Jose Luis Dominguez-Escrig},
  journal = {European Urology},
  year = {2026},
  month = jul,
  doi = {10.1016/j.eururo.2026.04.009},
  url = {https://pure.amsterdamumc.nl/en/publications/9d1df8a4-4100-473c-a241-adcdd9bc007c},
}
RIS
TY  - JOUR
TI  - EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) – A Summary of the 2026 Guidelines Update
AU  - Paolo Gontero
AU  - Paramananthan Mariappan
AU  - Benjamin Pradère
AU  - Bhavan P. Rai
AU  - Fredrik Liedberg
AU  - Éva Compérat
AU  - Jeremy Yuen‐Chun Teoh
AU  - Marco Moschini
AU  - Francesco Soria
AU  - Bas W.G. van Rhijn
AU  - Joyce Baard
AU  - Alison Jane Birtle
AU  - Maresa Botha
AU  - Otakar Čapoun
AU  - David D’Andrea
AU  - Edoardo Fiorini
AU  - A. Masson-Lecomte
AU  - Thomas Seisen
AU  - Shahrokh François Shariat
AU  - Emma J. Smith
AU  - Viktor Soukup
AU  - Robert Wood
AU  - Evanguelos N. Xylinas
AU  - Jose Luis Dominguez-Escrig
PY  - 2026
DA  - 2026/07/15
JO  - European Urology
DO  - 10.1016/j.eururo.2026.04.009
UR  - https://pure.amsterdamumc.nl/en/publications/9d1df8a4-4100-473c-a241-adcdd9bc007c
SN  - 0302-2838
SN  - 1421-993X
SN  - 1873-7560
ER  -